CAR T Cell Therapy for Brain Cancer Metastases
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 trial tests a new type of immune cell therapy (CAR T cells) designed to fight cancers that have spread to the brain. The cells are engineered to recognize and attack cancer cells that express a protein called CD70, and may help patients whose cancer has come back or progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed cancer diagnosis with CD70 protein found in your tumor tissue
- Cancer that has spread to the brain (metastases) that is recurring, progressing, or newly appeared
- Able to perform daily activities with minimal assistance (Karnofsky score of 70 or higher)
- Age 18 or older with adequate blood cell counts, kidney, and liver function
- Recent brain MRI scan (within 28 days) showing your metastases
- Willingness to use birth control for 24 weeks after treatment if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a customized immune-cell treatment (CAR T cells) for adults with newly diagnosed glioblastoma (GBM) whose tumors have enough CD70 protein. If you qualify, the goal is to see whether this treatment can better control the cancer by targeting it in the brain.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
This Phase 1 study tests a type of immune therapy (CAR T cells) for children with brain tumors that come back or do not respond to standard treatment. The cells are given after chemotherapy that temporarily lowers the body’s immune system, which may help the CAR T cells work better.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.